Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences : Magrolimab Gets FDA Breakthrough Therapy Designation in Myelodysplastic Syndrome

share with twitter share with LinkedIn share with facebook
09/15/2020 | 08:40am EDT

By Colin Kellaher

 

Gilead Sciences Inc. on Tuesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndrome.

The Foster City, Calif., biopharmaceutical company said the designation is based on positive results of an ongoing Phase 1b study, in which 91% percent of evaluable patients treated with magrolimab plus azacitidine achieved an objective response, with 42% achieving a complete remission.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.

Gilead said about 15,000 people in the U.S. each year are diagnosed with myelodysplastic syndrome, a type of cancer caused by poorly formed or dysfunctional blood cells in the bone marrow, adding that no new treatments have been approved in 14 years.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 


share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
09:33aGILEAD SCIENCES : Presents New Data from Antiviral Development Programs at IDWee..
AQ
10/19GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Kite's KTE-X19 for t..
AQ
10/19GILEAD SCIENCES : Presents New Data from Antiviral Development Programs at IDWee..
BU
10/16GILEAD SCIENCES : WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized ..
DJ
10/16GILEAD SCIENCES : FDA Says Remdesivir EUA Letter Of Authorization, Reissued Oct ..
RE
10/16GILEAD SCIENCES : Statement on the Solidarity Trial
PU
10/16GILEAD SCIENCES : WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized ..
DJ
10/16GILEAD SCIENCES : EU urged to review remdesivir supply deal after COVID-19 trial..
RE
10/16GLOBAL MARKETS LIVE : Gilead, Daimler, Pfizer…
10/16GILEAD SCIENCES : Kite Says CHMP Adopts Positive Opinion for Lymphoma Drug
DJ
More news
Financials (USD)
Sales 2020 24 005 M - -
Net income 2020 2 180 M - -
Net Debt 2020 3 105 M - -
P/E ratio 2020 37,6x
Yield 2020 4,43%
Capitalization 75 938 M 75 938 M -
EV / Sales 2020 3,29x
EV / Sales 2021 3,29x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,29 $
Last Close Price 60,57 $
Spread / Highest target 73,4%
Spread / Average Target 29,3%
Spread / Lowest Target -5,89%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.79%75 938
REGENERON PHARMACEUTICALS55.31%61 364
VERTEX PHARMACEUTICALS0.71%57 436
WUXI APPTEC CO., LTD.60.41%38 230
BEIGENE, LTD.81.90%27 326
GENMAB A/S55.65%23 862